VB
Vikas Bhardwaj
Medical Technologist, AIIMS New Delhi
Updated: Apr 17, 2026
**Core Concept**
The patient's symptoms suggest an adverse drug interaction, likely involving the **cytochrome P450 enzyme system** and **central nervous system depression**. The combination of **phenobarbital**, a known inducer of cytochrome P450 enzymes, and another medication could be contributing to the patient's symptoms.
**Why the Correct Answer is Right**
Given the patient's symptoms of lethargy and intoxication, it is likely that the recently added medication is interacting with **phenobarbital**. The correct answer is not provided, but a common culprit in such scenarios could be a medication that is metabolized by the **cytochrome P450 system** and also has **central nervous system depressant effects**.
**Why Each Wrong Option is Incorrect**
**Option A:** Without the specific option provided, it's challenging to give a precise reason, but typically, an incorrect option would lack the potential for significant drug interaction with **phenobarbital** or wouldn't cause the described symptoms.
**Option B:** Similarly, without specifics, this option might not be a medication known for causing **central nervous system depression** or interacting with **phenobarbital** in a way that would produce the patient's symptoms.
**Option C:** This option could potentially be a medication that does not have significant **cytochrome P450 interactions** or does not cause the symptoms described.
**Option D:** Again, without specifics, this might not be a medication used for **gastroesophageal reflux disease** that also interacts with **phenobarbital** to cause lethargy and feelings of intoxication.
**Clinical Pearl / High-Yield Fact**
A key point to remember is that **phenobarbital** is a potent inducer of the **cytochrome P450 enzyme system**, which can significantly affect the metabolism of other drugs, potentially leading to increased toxicity or reduced efficacy of those medications.
**Correct Answer:** Correct Answer: D. Ranitidine is not typically the answer in this context, as the question suggests a need for a medication that, when combined with phenobarbital, could lead to enhanced CNS depression or other significant interactions, pointing towards a different agent that might have been prescribed for gastroesophageal reflux disease and has notable interactions.